Lux Biosciences began a phase 1 study of LX214, a proprietary topical ophthalmic solution containing the next-generation calcineurin inhibitor voclosporin.
Advertisement
Advertisement
Lux Biosciences began a phase 1 study of LX214, a proprietary topical ophthalmic solution containing the next-generation calcineurin inhibitor voclosporin.
.png "Optometry Times"){kind=logo}
